Viruses are obligate intracellular pathogens that utilize cellular machinery for many aspects of their propagation and effective egress of virus particles from host cells is one important determinant of virus infectivity. Hijacking host cell processes applies in particular to the hepatitis B virus (HBV), as its DNA genome with about 3 kb in size is one of the smallest viral genomes known. HBV is a leading cause of liver disease and still displays one of the most successful pathogens in human populations worldwide. The extremely successful spread of this virus is explained by its efficient transmission strategies and its versatile particle types, including virions, empty envelopes, naked capsids, and others. HBV exploits distinct host trafficking machineries to assemble and release its particle types including nucleocytoplasmic shuttling transport, secretory, and exocytic pathways, the Endosomal Sorting Complexes Required for Transport pathway, and the autophagy pathway. Understanding how HBV uses and subverts host membrane trafficking systems offers the chance of obtaining new mechanistic insights into the regulation and function of this essential cellular processes. It can also help to identify potential targets for antiviral interventions. Here, I will provide an overview of HBV maturation, assembly, and budding, with a focus on recent advances, and will point out areas where questions remain that can benefit from future studies. Unless otherwise indicated, almost all presented knowledge was gained from cell culture-based, HBV in vitro-replication and in vitro-infection systems.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/boc.202200060 | DOI Listing |
Niger Med J
January 2025
Department of Obstetrics and Gynaecology, Federal University of Health Sciences, Azare, Bauchi State, Nigeria.
Background: Infection with the human immunodeficiency virus and hepatitis viruses B and C have been reported to be endemic in some Nigeria's institutions of higher learning. Several studies have reported varying prevalence rates for hepatitis B and C viruses and HIV among undergraduate students in Nigerian universities.
Methodology: A cross-sectional descriptive prevalence study of hepatitis B and C viruses and HIV among students at Federal University of Health Sciences, Azare conducted on the 2nd of December 2023.
Open Forum Infect Dis
January 2025
Division of Infectious Diseases, St Michael's Hospital, Toronto, Canada.
Background: Hepatitis C virus (HCV) has emerged as a sexually transmitted infection in gay, bisexual, and other men who have sex with men (GBM). We estimated the seroprevalence and incidence of HCV infection and examined patterns of HCV testing among GBM using human immunodeficiency virus preexposure prophylaxis (PrEP) in Ontario, Canada.
Methods: We analyzed data from the Ontario PrEP Cohort Study (ON-PrEP), a prospective cohort of PrEP users from 10 Ontario clinics.
Open Forum Infect Dis
January 2025
Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario, Canada.
Background: The burden of hepatitis C virus (HCV)-related hospitalizations is substantial, particularly among people with HIV and HCV. In Ontario, Canada, use of direct-acting antivirals (DAAs) increased following policies removing fibrosis-stage restrictions and approving of pangenotypic agents in 2017 and 2018, respectively. We examined the impact of expanded DAA access on HCV-related hospitalizations in people with HIV.
View Article and Find Full Text PDFInfect Drug Resist
January 2025
Department of Hepatology and Gastroenterology, Tianjin First Central Hospital, Tianjin, 300192, People's Republic of China.
Purpose: The research intended to present prospective data on the long-term prognosis of individuals with hepatitis C virus (HCV) infection who received direct-acting antiviral agent (DAA) treatment.
Patients And Methods: Patients who received DAA treatment at Tianjin Third Central Hospital and Tianjin Second People's Hospital were prospectively enrolled and subsequently underwent a longitudinal follow-up. This research monitored occurrences of virological relapse, hepatocellular carcinoma (HCC), mortality, and liver disease progression.
EClinicalMedicine
February 2025
Department of Obstetrics and Gynecology, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China.
Progress towards achieving global elimination of hepatitis B virus (HBV) by 2030 remains unsatisfactory. Prevention of mother to child transmission is crucial but current Clinical Practice Guidelines (CPGs) gave diverse recommendations, creating confusion and leading to significant challenges in the practical implementation across various regions owing to global inequity. We reviewed 47 CPGs on the management of hepatitis B during pregnancy against twelve important clinical questions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!